Marzia Salvucci

Ravenna, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.

PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.

Journal: Annals of hematology
Published: March 26, 2025

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.

Journal: Haematologica
Published: October 13, 2021

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.

Journal: Targeted oncology
Published: July 20, 2021

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.

Journal: Blood
Published: August 23, 2019

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Journal: Blood advances
Published: August 20, 2019

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Journal: Cancer
Published: October 30, 2017

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Journal: Oncotarget
Published: November 01, 2016

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Journal: American journal of hematology
Published: August 10, 2016

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Journal: Haematologica
Published: February 23, 2016

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.

Journal: Oncotarget
Published: December 17, 2015

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Journal: Haematologica
Published: April 27, 2015

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: September 02, 2013
Showing 1-12 of 14

Last Updated: 09/26/2026